Vertex Pharmaceuticals Inc. (VRTX) Monday revealed positive results from an early-stage viral kinetic study of the nucleotide analogue ALS-2200 for the treatment of hepatitis C.
As per the study results, there was a median 4.54 log10 reduction in hepatitis C virus (HCV) RNA in people with genotype 1 chronic hepatitis C who were new to treatment after seven days of dosing with 200 mg of ALS-2200 once daily. ALS-2200 was well-tolerated and no patients discontinued due to adverse events.
Vertex said that based on the positive data, it plans to begin Phase 2 studies this year of 12-week all-oral regimens including ALS-2200 in people with genotype 1 hepatitis C, pending discussions with regulatory agencies.
Vertex said it plans conduct a study to assess ALS-2200 in combination with Incivek (telaprevir), the company's approved protease inhibitor for people with genotype 1 hepatitis C, and a study of ALS-2200 in combination with ribavirin.
These studies will evaluate 12 total weeks of treatment with a primary endpoint of SVR12 (sustained viral response: undetectable hepatitis C virus 12 weeks after the end of treatment) in people with genotype 1 hepatitis C.
Also today, Vertex reported a smaller quarterly loss on a surge in sales. It however slashed its full-year 2012 revenue expectations for Incivek, citing the recent downward trend in the number of patients initiating treatment within the hepatitis C market.
VRTX closed Monday at $49.96, up 1.30%, on a volume of 2.2 million shares on the Nasdaq. In after hours, the stock rallied $3.04 or 6.08%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.